Home > Celia Oreja-Guevara, EAN 2020 – Regional Findings From The Phase 3 PREVENT Study in NMOSD

Celia Oreja-Guevara, EAN 2020 – Regional Findings From The Phase 3 PREVENT Study in NMOSD

Published Online: June 8th 2020

Great to have an opportunity to speak with Celia Oreja-Guevara (University Hospital San Carlos and University Complutense, Madrid, Spain) around the highlights of her presentation entitled: Regional outcomes of eculizumab treatment in patients with aquaporin-4 immunoglobin G-positive neuromyelitis optica spectrum disorder: findings from the phase 3 PREVENT study (ClinicalTrials.gov Identifier: NCT01892345).

Questions 1. What were the aims of the PREVENT study? (0:05)
2. What were the baseline regional differences in patient characteristics and use of immunosuppressive therapies? (
3. What were the outcomes across different regions? (
4. What is the broader significance of these findings? (

Speaker disclosure: Celia Oreja-Guevara reports that research funding for the study discussed in this video interview was provided by Alexion Pharmaceuticals.

Support: Interview and filming supported by Touch Medical Media.

Filmed at the 6th Congress of the European Academy of Neurology (EAN) and 1st EAN Virtual Congress, May 2020.

Share this Video
Related Videos In Neuroimmunology
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-blueavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar